The spin-off completes Glycotope’s refocusing solely on drug discovery and development, using its proprietary technology platform to develop tumor-specific monoclonal antibodies. FyoniBio, now part of Canton Biologics Group, will continue the contract development services business and offer a wide range of ISO-9001 compliant services, from cell line development to clinical bioanalysis.
“We look forward to collaborating with FyoniBio for our development needs, while Glycotope’s renewed focus solely on drug discovery and development strengthens our profile as a platform company for tumor-targeting antibodies with specificity. unique,” said Henner Kollenberg, CEO of Glycotope.
Xiao Shen, Founder and CEO of Canton Biologics, said, “The acquisition of FyoniBio not only supports Canton Biologics’ international growth strategy, but more importantly, through FyoniBio, Canton Biologics can significantly expand our technology platforms and scope of our services to better support international customers. in Europe and worldwide.